This is my 2 cents. MACK will announce P3 result of their MM-398 in 4Q for second line treatment of metastatic pancreatic cancer. If that is positive, then MACK will eat THLD's lunch because they are both targeting the hypoxic regions of the tumor. If 398 is negative, then THLD should see a big jump in PPS.
HWsimp.. below is right and wrong on a couple of points, imo.
First, the stock is mostly institutionally-owned with a low float and few free shares (and little retail interest). With no pending news, it's been easy for MM's to walk it down.
But their drug is significantly better and different enough from ZIOP's that it could be a blockbuster
I'm not ranger, but I can answer this. The market is going through a correction right now, which should last another 2-3 months in all likelihood. Given that THLD does not have any significant catalysts coming in the next few months, it is taking a bigger hit, and will likely continue to do so. On top of that, THLD's drug is very similar in chemistry to ZIOP's perisifone (spelling?), which proved to be utterly useless. THLD's sarcoma drug is likely going to suffer the same fate.